Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Microbix Biosystems in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.39.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Microbix Biosystems. This Buy consensus rating has held steady for over two years.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.